Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure–strain analysis
Clinical Research in Cardiology · 2026
DOI: 10.1007/s00392-026-02855-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von S Scholtz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ruhr University Bochum, Heart- and Diabetescenter NRW, Department of General and Interventional Cardiology/Angiology, Bad Oeynhausen, Germany. sschol…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Ventricular Function, Left, Stroke Volume, Uracil. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Diabetes Centre North Rhine-Westphalia (DKZ NRW).
Abstract (Originalsprache)
Background
Mavacamten is the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addressing hypercontractility and left ventricular outflow tract (LVOT) obstruction.
Objectives
This study evaluates left ventricular performance by non-invasive measurements of pressure–strain loops in patients treated with Mavacamten.
Methods
In 36 symptomatic oHCM patients, pressure–strain analysis was performed prior to 3 and 12 months after Mavacamten therapy. Echocardiographic measurements included LVOT gradient, left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), left atrial strain (LAS), peak strain time dispersion (PSD), and myocardial work parameters (global work index (GWI), global constructive work (GCW), global wasted work (GWW), and global work efficiency (GWE)). Clinical status was evaluated using the New York Heart Association (NYHA) class and stress biomarkers (NTproBNP and high-sensitivity troponin I).
Results
Mavacamten therapy significantly reduced LVOT gradients at rest and under provocation. Gradients decreased from 69 ± 36 to 24 ± 27 mmHg ( p < 0.001) at 3 months and further to 11 ± 6 mmHg ( p = 0.003) at 12 months. Provoked gradients decreased from 113 ± 33 to 50 ± 31 mmHg ( p < 0.001) at 3 months and to 31 ± 19 mmHg ( p = 0.01) at 12 months. Clinical symptoms also improved. LVEF was 68 ± 6% at baseline and decreased mildly to 62 ± 5% ( p = 0.003), while GLS and LAS remained unchanged. PSD decreased mildly from 116 ± 56 to 97 ± 36 ms and further to 93 ± 38 ms, but this was not statistically significant ( p = 0.07). Under Mavacamten, GWE remained stable. In contrast, GWI, GCW, and GWW decreased significantly from baseline to 3 months (GWI, 2098 ± 700 to 1610 ± 440 mmHg%, p < 0.001; GCW, 2514 ± 776 to 1951 ± 466 mmHg%, p < 0.001; GWW, 312 ± 163 to 249 ± 177 mmHg%, p = 0.003), with only mild, non-significant further reductions at 12 months (1538 ± 402, 1901 ± 380, and 207 ± 124 mmHg%, respectively; p = 0.67, p = 0.74, p = 0.30).
Conclusion
Myocardial work indices derived from non-invasive pressure–strain analysis were feasible to obtain in patients with oHCM in this study. Mavacamten therapy decreases workload index, constructive and wasted work, and synchronizes myocardial contractility, reflecting normalization of myocardial energetics. These findings reinforce the role of Mavacamten as a targeted therapy in oHCM. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ruhr University Bochum, Heart- and Diabetescenter NRW, Department of General and Interventional Cardiology/Angiology, Bad Oeynhausen, Germany. sscholtz@hdz-nrw.de.
- Ruhr University Bochum, Heart- and Diabetescenter NRW, Department of General and Interventional Cardiology/Angiology, Bad Oeynhausen, Germany.
- Comprehensive Heart Failure Center (CHFC), University Clinic Würzburg, Würzburg, Germany.
- Ruhr University Bochum, Heart- and Diabetescenter NRW, Department of General and Interventional Cardiology/Angiology, Bad Oeynhausen, Germany. jreil@hdz-nrw.de.
Förderung
- Heart and Diabetes Centre North Rhine-Westphalia (DKZ NRW)
Zitieren
APA
Scholtz, S., Coppée, C., Mohemed, K., Potratz, M., Langkamp, F., Rudolph, V., Maack, C., Scholtz, W., Sequeira, V., & Reil, J. C. (2026). Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure–strain analysis. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-02855-0
Vancouver
Scholtz S, Coppée C, Mohemed K, Potratz M, Langkamp F, Rudolph V, et al. Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure–strain analysis. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-02855-0
BibTeX
@article{Scholtz2026,
author = {Scholtz, S and Coppée, C and Mohemed, K and Potratz, M and Langkamp, F and Rudolph, V and Maack, C and Scholtz, W and Sequeira, V and Reil, J-C},
title = {Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure–strain analysis},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-026-02855-0}
}
EUVIMED